within Pharmacolibrary.Drugs.R_RespiratorySystem.R03C_AdrenergicsForSystemicUse.R03CC12_Bambuterol;

model Bambuterol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.1,
    Cl = 2.5277777777777778e-06,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.0012900000000000001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0013833333333333334,
    Tlag = 19.8,
    Vdp = 0.00227,
    k12 = 3.5e-06,
    k21 = 3.5e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Bambuterol</td></tr><tr><td>ATC code:</td><td>R03CC12</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.29</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.13</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Bambuterol is a long-acting beta2-adrenergic agonist (LABA) used as a bronchodilator for the management of asthma and chronic obstructive pulmonary disease (COPD). It is a prodrug of terbutaline. Bambuterol is administered orally and is approved and used in some countries for maintenance treatment of asthma.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, typically after single oral administration.</p><h4>References</h4><ol><li><p>Ahlström, H, et al., &amp; Rosenborg, J (1999). Pharmacokinetics of bambuterol during oral administration to asthmatic children. <i>British journal of clinical pharmacology</i> 48(3) 299–308. DOI:<a href=\"https://doi.org/10.1046/j.1365-2125.1999.00028.x\">10.1046/j.1365-2125.1999.00028.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10510139/\">https://pubmed.ncbi.nlm.nih.gov/10510139</a></p></li><li><p>Ye, Y, et al., &amp; Tan, W (2015). The Lipid-lowering Effects of R-bambuterol in Healthy Chinese Volunteers: A Randomized Phase I Clinical Study. <i>EBioMedicine</i> 2(4) 356–364. DOI:<a href=\"https://doi.org/10.1016/j.ebiom.2015.02.006\">10.1016/j.ebiom.2015.02.006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26137575/\">https://pubmed.ncbi.nlm.nih.gov/26137575</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03CC12 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Bambuterol;
